Compare FLXS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | SLGL |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.0M | 247.1M |
| IPO Year | 1995 | 2016 |
| Metric | FLXS | SLGL |
|---|---|---|
| Price | $44.84 | $76.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 24.3K | 17.5K |
| Earning Date | 04-20-2026 | 03-19-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ 85.86 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $441,073,000.00 | N/A |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $3.56 | $223.84 |
| P/E Ratio | $17.99 | ★ N/A |
| Revenue Growth | ★ 6.86 | N/A |
| 52 Week Low | $29.38 | $0.40 |
| 52 Week High | $59.95 | $97.97 |
| Indicator | FLXS | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 53.39 |
| Support Level | $43.54 | $66.47 |
| Resistance Level | $47.99 | $95.83 |
| Average True Range (ATR) | 1.74 | 10.84 |
| MACD | -0.01 | -0.80 |
| Stochastic Oscillator | 61.31 | 62.97 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.